Neurobiological correlates of a putative risk allele for Alzheimer's disease on chromosome 12q

Neurology

Volumn 52, Issue 4, 1999, Pages 725-732

  Zubenko, George S ^a,b,c   Hughes III, Hugh B ^a   Stiffler, J Scott ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Carnegie Mellon University   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CHROMOSOME 12Q; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE SEVERITY; FEMALE; GENE LOCUS; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME; GENOTYPE; HUMAN; MALE; MORPHOMETRICS; NEUROCHEMISTRY; NEUROPATHOLOGY; PRIORITY JOURNAL;

EID: 0033541096     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.4.725     Document Type: Article

References (38)

1. Zubenko GS. Molecular neurobiology of Alzheimer's disease (syndrome?) Harv Rev Psychiatry 1997;5:177-213.
2. Myklebost O, Rogne S. A physical map of the apolipoprotein gene cluster on human chromosome 19. Hum Genet 1988;78: 244-247.
3. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ∈4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
4. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
5. APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A metaanalysis. JAMA 1997;278:1349-1356.
6. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type-4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
7. Schmechel D, Saunders A, Strittmatter W, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
8. Zubenko GS, Stiffler S, Stabler S, et al. Association of the apolipoprotein E ∈4 allele with clinical subtypes of autopsyconfirmed Alzheimer's disease. Am J Med Genet (Neuropsychiatr Genet) 1994;54:199-205.
9. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105.
10. Mirra SS, Keyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Neurology 1991;41:479-486.
11. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's disease. Nat Genet 1994;7:180-184.
12. Blacker D, Wilcox MA, Laird NM, et al. Alpha-2-macroglobulin is genetically associated with Alzheimer's disease. Nat Genet 1998;19:357-360.
13. Pericak-Vance MA, Bass MP, Yamaoka LH, et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997;278: 1237-1241.
14. Zubenko GS, Wusylko M, Boller F, Cohen BM, Teply I. Family study of platelet membrane fluidity in Alzheimer's disease. Science 1987;238:539-542.
15. Chakravarti A, Slaugenhaupt S, Zubenko GS. Inheritance pattern of platelet membrane fluidity in Alzheimer's disease. Am J Hum Genet 1989;44:799-805.
16. Zubenko GS, Teply I, Winwood E, et al. Prospective study of increased platelet membrane fluidity as a risk factor for Alzheimer's disease: results at 7.5 years. Am J Psychiatry 1999; 156:50-57.
17. Davis RE, Miller S, Herrnstadt C, et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with lateonset Alzheimer disease. Proc Natl Acad Sci USA 1997;94: 4526-4531.
18. Zubenko GS, Hughes HB, Stiffler JS, Hurtt MR, Kaplan BB. A genome survey for novel Alzheimer disease risk loci: results at 10-cM resolution. Genomics 1998;50:121-128.
19. GDB™ Human Genome Database [database online]. Baltimore, MD: Johns Hopkins University, 1990-. Updated daily. Available from Internet: URL http://www.gdb.org [cited 18 August 1998; GDB node: USA, http://www.gdb.org/] GDB Data Type: Amplimer; Object Name: CHLC.ATA29A06. P17037; Accession ID: GDB: 684039; GDB Data Type: Amplimer; Object Name: CHLC.GATA11B02.P7173; Accession ID: GDB: 686442; GDB Data Type: Amplimer; Object Name: CHLC.ATA27A06.P17004; Accession ID: GDB: 683970; GDB Data Type: Gene; Object Name: A2M; Accession ID: GDB: 119639; Mapview Display of GDB Maps: GDB Comprehensive Map-Chr. 12.
20. Moossy J, Zubenko GS, Martinez AJ, Rao GR. Bilateral symmetry of morphologic lesions in Alzheimer's disease. Arch Neurol 1988;45:251-254.
21. Zubenko GS, Moossy J, Hanin I, Martinez AJ, Rao GR, Kopp U. Bilateral symmetry of cholinergic deficits in Alzheimer's disease. Arch Neurol 1988;45:255-259.
22. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8.
23. Lippa CF, Smith TW, Swearer JM. Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 1994;35:81-88.
24. Dickson DW, Crystal H, Mattiace LA, et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol 1989;78:572-584.
25. Oppenheimer DR, Esiri MM. Diseases of the basal ganglia, cerebellum and motor neurons. Parkinson's disease (paralysis agitans). In: Adams JH, Duchen LW, eds. Greenfield's neuropathology, 5th ed. New York: Oxford University Press, 1992: 991-997.
26. Brion S, Plas J, Jeanneau A. La maladie de Pick. Point de vue anatomo-clinique. Rev Neurol 1991;147:693-704.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. Washington, DC: American Psychiatric Association, 1980.
28. Huff FJ, Auerbach J, Chakravarti A, Boller F. Risk of dementia in relatives of patients with Alzheimer's disease. Neurology 1988;38:786-790.
29. Saller CF, Salama AI. Rapid automated analysis of biogenic amines and their metabolites using reversed-phase high performance liquid chromatography with electrochemical detections. J Chromatogr 1984;309:287-298.
30. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990;47: 209-214.
31. Fonnum F. Radiochemical microassays for the determination of choline acetyltransferase and acetylcholinesterase activity. Biochem J 1969;115:465-472.
32. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
33. Zubenko GS, Moossy J, Martinez AJ, Rao GR, Kopp U, Hanin I. A brain regional analysis of morphologic and cholinergic abnormalities in Alzheimer's disease. Arch Neurol 1989;46: 634-638.
34. Förstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy body variant of Alzheimer's disease: clinical and pathological findings. Br J Psychiatr 1993;162:385-392.
35. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993; 43:1927-1934.
36. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. NeuroReport 1994;5:747-749.
37. Zubenko GS. Clinicopathological and neurochemical correlates of major depression and psychosis in primary dementia (in the IPA-sponsored Proceedings of the Consensus Conference on Behavioral Disturbances of Dementia). Intl Psychogeriatrics 1996;8:219-223.
38. Zubenko GS, Moossy J. Major depression in primary dementia: clinical and neuropathologic correlates. Arch Neurol 1988; 45:1182-1186.